Physician profile
Christa Setser
NPI 1659980373
$3,884.98
in general payments reported to CMS, 2019-2025
17 companies · $926 in 2025
The $926 reported for 2025 was more than what 79% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $172 · 2022: $407 · 2023: $1,032 · 2024: $1,348 · 2025: $926.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,259 · Education: $46.91.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,259.11 |
| Education | $46.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $738.83 | 2022-2025 | |
| Neurocrine Biosciences, INC. | $652.96 | 2021-2025 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $438.45 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Axsome Therapeutics, INC. | $390.31 | 2023-2025 | Auvelity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $328.58 | 2023-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $312.82 | 2023-2025 | Austedo Xr, Uzedy |
| Vanda Pharmaceuticals INC. | $191.59 | 2024-2025 | Hetlioz, Fanapt |
| Janssen Pharmaceuticals, INC | $178.24 | 2024-2025 | Spravato |
| Alkermes, INC. | $151.08 | 2021-2025 | Aristada, Lybalvi, Vivitrol |
| Lundbeck LLC | $145.82 | 2021-2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $103.20 | 2022-2024 | Trintellix |
| E.R. Squibb & Sons, L.L.C. | $77.73 | 2024-2025 | Cobenfy |
| Novo Nordisk INC | $64.74 | 2022-2024 | Rybelsus, Ozempic |
| Lilly USA, LLC | $51.75 | 2022-2024 | Mounjaro |
| Exact Sciences Corporation | $24.19 | 2025 | Cologuard Collection Kit |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $19.65 | 2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.04 | 2023 | Xifaxan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christa Setser listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.